- Home
- CMPS vs INBX Comparison
CMPS vs INBX Comparison
Compare CMPS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMPS | INBX |
|---|---|---|
| Founded | 2020 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2020 | 2024 |
Fundamental Metrics
Financial Performance| Metric | CMPS | INBX |
|---|---|---|
| Price | $11.28 | $82.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | $25.38 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 4.6M | 295.1K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $3.92 | $20.55 |
| 52 Week High | $15.40 | $155.29 |
Technical Indicators
Market Signals| Indicator | CMPS | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 35.49 |
| Support Level | $11.14 | $71.31 |
| Resistance Level | $14.92 | $85.97 |
| Average True Range (ATR) | 0.93 | 5.92 |
| MACD | -0.30 | -0.98 |
| Stochastic Oscillator | 5.29 | 2.68 |
Price Performance
Historical ComparisonAbout CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.